Polpharma Celebrates Being First With Natalizumab In Europe

Proposed Biosimilar Rival To Tysabri Begins EMA Review; Sandoz Has Marketing Rights

 
• By David Wallace
EU flag medal 1st first place
Polpharma has claimed the first biosimilar natalizumab filing • Source: Shutterstock

More from Biosimilars

More from Products